Day: February 24, 2021

Denver, CO, Feb. 24, 2021 (GLOBE NEWSWIRE) — Intrepid Potash Inc. (NYSE: IPI) plans to release its fourth quarter 2020 financial results on Monday, March 1, 2021, after the market closes. Intrepid will host a conference call on Tuesday, March 2, 2021 at 12:00 p.m. Eastern Time to discuss the results and other operating and financial matters and to answer investor questions.Management invites you to listen to the conference call by using the dial-in number 1-800-319-4610 from the U.S. and Canada, or +1-631-891-4304 from other countries. The call will also be streamed live on Intrepid’s website, intrepidpotash.com.A recording of the conference call will be available approximately two hours after the completion of the call at intrepidpotash.com or by dialing 1-800-319-6413 from the U.S. and Canada, or +1-631-883-6842 from other...

BEIJING, Feb. 24, 2021 (GLOBE NEWSWIRE) — Glory Star New Media Group Holdings Limited (NASDAQ: GSMG) (“Glory Star” or the “Company”), a leading mobile and online digital media and entertainment company in China, today announced the close of its underwritten public offering of an aggregate of 3,810,976 ordinary shares of the Company, together with warrants to purchase 3,810,976 ordinary shares of the Company, at a public offering price of $3.28 per share and associated warrant. After deducting underwriting discounts and commissions and other estimated offering expenses, the net proceeds of the public offering were approximately $11.3 million.Univest Securities, LLC was the sole book-running manager for the offering.The Company intends to use the net proceeds from the offering primarily for working capital and other general corporate...

– G1’s COSELA™ (trilaciclib) Approved by FDA as First and Only Therapy to Decrease the Incidence of Chemotherapy-Induced Myelosuppression; Commercial Availability Expected in Early March –– Launch Underway, including Medical Affairs, Promotional, and Educational Activities to Introduce COSELA to Oncologists and Oncology Nurses and Build Awareness of Myelosuppression –– On-track to Initiate Three Additional Clinical Trials in 1H2021 to Assess the Potential Myeloprotection and/or Anti-Tumor Efficacy Benefit of COSELA in Multiple Cancers –– Management to Host Webcast and Conference Call today at 4:30 PM ET –RESEARCH TRIANGLE PARK, N.C., Feb. 24, 2021 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today provided a corporate and financial update...

MITCHEL FIELD, N.Y., Feb. 24, 2021 (GLOBE NEWSWIRE) — Frequency Electronics, Inc. (“FEI” or the “Company”) (NASDAQ-FEIM) today announced the selection of its high performance oscillators and microwave frequency generation units for ultimate application on a key US government satellite system. This first phase contract is valued at approximately $17M, with a four year period of performance. A Phase 2 follow-on contract for additional flight units is anticipated.FEI CEO, Stan Sloane, commented, “We are extremely pleased that our flagship satellite products have been selected for another critical military program. FEI continues to be the go-to provider of technically advanced, high-stability oscillators, as well as RF and microwave sources for space. This reflects continuing customer confidence in our ability to deliver critical components...

— NUZYRA Generated Net U.S. Sales of $12.4 Million in the Fourth Quarter 2020; a 14% Increase Over the Third Quarter 2020— Paratek Expects Full Year 2021 Total Revenue Between $166 and $177 MillionBOSTON, Feb. 24, 2021 (GLOBE NEWSWIRE) — Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel life-saving therapies for life-threatening diseases or other public health threats for civilian, government and military use, today reported financial results and provided an update on corporate activities for the quarter and year ended December 31, 2020.

ROCHESTER, Mich., Feb. 24, 2021 (GLOBE NEWSWIRE) — OptimizeRx Corp. (Nasdaq: OPRX), a leading provider of digital health solutions for life science companies, physicians and patients, reported results for the fourth quarter and full year ended December 31, 2020. Quarterly and full year comparisons are to the same year-ago period.Financial HighlightsRevenue in the fourth quarter of 2020 increased 123% to a record $16.4 million, with the full year of 2020 up 76% to a record $43.3 million.Gross profit in the fourth quarter of 2020 increased 92% to $8.6 million.GAAP net income totaled $1.4 million or $0.08 per diluted share in the fourth quarter.Non-GAAP net income in the fourth quarter totaled $2.7 million or $0.16 per diluted share (see definition of this non-GAAP measure and reconciliation to GAAP, below).Cash and cash equivalents...

JENA, Germany, Feb. 24, 2021 (GLOBE NEWSWIRE) — InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced today that it has commenced an underwritten public offering of common shares of the Company. For each common share purchased, an investor will also receive a warrant to purchase a common share of the Company. The Company intends to use the net proceeds from the offering primarily to fund research and development expenses for its clinical and preclinical research and development activities and for working capital and general corporate purposes. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.Guggenheim...